Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension

Poms, Abby; Kingman, Martha
December 2011
Critical Care Nurse;Dec2011, Vol. 31 Issue 6, pe1
Academic Journal
Pulmonary arterial hypertension is a progressive disease characterized by vascular proliferation and vasoconstriction of the small pulmonary arteries that eventually leads to right-sided heart failure and death. Patients often initially have symptoms such as shortness of breath, fatigue, and edema; later in the disease, presyncope and syncope are common. Patients with progressive pulmonary arterial hypertension despite oral therapy and/or with severe disease typically require treatment with a prostanoid. Inhaled treprostinil (Tyvaso) is a prostacyclin analog indicated for the treatment of pulmonary arterial hypertension to increase walk distance in patients with symptoms classified as New York Heart Association functional class III. Inhaled treprostinil was approved by the Food and Drug Administration in July 2009. This article provides a brief overview of the pathophysiology of pulmonary arterial hypertension and reviews the mechanism of action, key clinical data, and the practical management of inhaled treprostinil in patients with pulmonary arterial hypertension.


Related Articles

  • Aztreonam lysine for inhalation: New formulation of an old antibiotic. Zeitler, Kristen; Salvas, Brian; Stevens, Vanessa; Brown, Jack // American Journal of Health-System Pharmacy;1/15/2012, Vol. 69 Issue 2, p107 

    Purpose. The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Summary. Inhaled aztreonam, a newly formulated lysine salt of the original monobactam antibiotic, is approved for...

  • Nomegestrol Acetate/Estradiol: In Oral Contraception. Yang, Lily P. H.; Plosker, Greg L. // Drugs;2012, Vol. 72 Issue 14, p1917 

    Nomegestrol acetate/estradiol is a combined oral contraceptive with approval in many countries. This fixed-dose combination tablet contains nomegestrol acetate, a highly selective progestogen, and estradiol, natural estrogen. It is the first monophasic combine oral contraceptive to contain...

  • Carfilzomib: In Relapsed, or Relapsed and Refractory, Multiple Myeloma. Mccormack, Paul L. // Drugs;2012, Vol. 72 Issue 15, p2023 

    Intravenous carfilzomib is a peptide epoxyketone, next-generation proteasome inhibitor, which has been granted accelerated approval in the US for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent...

  • Improving the management of asthma in older adults. Carnegie, Elaine; Jones, Angela // Nursing Standard;11/27/2013, Vol. 28 Issue 13, p50 

    Older people with asthma are a discrete patient group that requires specialist nursing skills and knowledge. They have specific and sometimes hidden needs that will affect their quality of life unless these are addressed by caring and competent nurses who have an interest in asthma. It is...

  • Circulating Endothelial Cells in Refractory Pulmonary Hypertension in Children: Markers of Treatment Efficacy and Clinical Worsening. Levy, Marilyne; Bonnet, Damien; Mauge, Laetitia; Celermajer, David S.; Gaussem, Pascale; Smadja, David M. // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Background: Pulmonary vasodilators in general and prostacyclin analogues in particular have improved the outcome of patients with pulmonary arterial hypertension (PAH). Endothelial dysfunction is a key feature of PAH and we previously described that circulating endothelial cell (CEC) level could...

  • Riociguat: A Review of Its Use in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension. Garnock-Jones, Karly // Drugs;Nov2014, Vol. 74 Issue 17, p2065 

    Riociguat (Adempas), a soluble guanylate cyclase stimulator, is a new, first-in-class drug approved for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) [inoperable or persistent/recurrent following surgery] or pulmonary arterial hypertension (PAH). It has...

  • Nonprescription Epinephrine Metered-Dose Inhaler: To Be or Not To Be. Blake, Kathryn; Raissy, Hengameh // Pediatric Allergy, Immunology & Pulmonology;Sep2014, Vol. 27 Issue 3, p143 

    A new product, Epinephrine HFA, is being considered by the Food and Drug Administration (FDA) for marketing approval as a nonprescription bronchodilator inhaler for the treatment of the 'temporary relief of mild symptoms of intermittent asthma in adults and children 12 years of age and older.'...

  • Budesonide/Formoterol Turbuhaler®: A Review of its Use in Chronic Obstructive Pulmonary Disease. Scott, Lesley J. // Drugs;2012, Vol. 72 Issue 3, p395 

    Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous, progressive inflammatory disease that imposes considerable economic and health-care burdens on society, with the disease predicted to remain a leading cause of mor-bidity and mortality worldwide in the future. Current...

  • Indacaterol: A Review of its Use as Maintenance Therapy in Patients with Chronic Obstructive Pulmonary Disease. McKeage, Kate // Drugs;2012, Vol. 72 Issue 4, p543 

    Indacaterol inhalation powder (Onbrez® Breezhaler®) is a long-acting, selective ß2-adrenoceptor agonist that is indicated for the maintenance bronchodilator treat-ment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD). This article reviews the clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics